Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289969 | 1.00 | EPHX1 (0.39) | EPHX1MEN1KMT2ASLC6A2TAAR1 | |
| SCHEMBL334898 | 1.00 | EPHX1 (0.39) | EPHX1MEN1KMT2ASLC6A2TAAR1 | |
| SCHEMBL9234671 | 0.81 | AGXT (0.34) | MEN1KMT2ATAAR1CYP2A6CYP1A2 | |
| SCHEMBL3263940 | 0.81 | MEN1 (0.41) | MEN1KMT2ATAAR1 | |
| SCHEMBL9232952 | 0.81 | SLC18A3 (0.35) | TAAR1SIGMAR1 | |
| SCHEMBL3276592 | 0.81 | EPHX1 (0.33) | EPHX1MEN1KMT2ATDP1CYP1A2 | |
| SCHEMBL9234577 | 0.79 | SLC6A4 (0.47) | SLC6A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL9090132 | 0.79 | TSHR (0.41) | EPHX1MEN1KMT2ASLC6A2TAAR1 | |
| SCHEMBL6636811 | 0.79 | SRR (0.41) | EPHX1CYP1A2 | |
| SCHEMBL1099896 | 0.78 | ALDH1A1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59076039-A | — | — | None | — | — | JP | disclosed |
| US-10413559-B2 | Method for treating demyelinating disease | OCHANOMIZU UNIVERSITY (JP) | 2019-09-17 | — | — | US | disclosed |
| EP-2949329-B1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | UNIV OCHANOMIZU (JP) | 2019-05-01 | — | — | EP | disclosed |
| US-20150352132-A1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | OCHANOMIZU UNIVERSITY (JP) | 2015-12-10 | — | — | US | disclosed |
| EP-2949329-A1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | Ochanomizu University (JP) | 2015-12-02 | — | — | EP | disclosed |
| US-8946211-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8618144-B2 | Pyrrolidine-derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP (US) | 2013-12-31 | — | — | US | disclosed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| EP-2098237-B1 | ANALGESIC AGENT COMPRISING CYCLIC PHOSPHATIDIC ACID DERIVATIVE | OCHANOMIZU UNIVERSITY (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-20120094984-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-1616852-A1 | PROCESS FOR PRODUCING BETA-HYDROXYESTER | DAISO CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-0821719-B1 | LIQUID CRYSTAL COMPOUNDS HAVING A CHIRAL FLUORINATED TERMINAL PORTION | MINNESOTA MINING & MFG (US) | 2003-01-02 | — | — | EP | disclosed |
| US-5977116-A | Piperazine, piperidine and tetrahydropyridine derivatives | MERCK SHARP & DOHME LTD. (GB) | 1999-11-02 | — | — | US | disclosed |
| US-5972241-A | ELECTROOPTICAL APPLICATIONS, IN PARTICULAR THOSE WHICH REQUIRE COMPACT, ENERGY-EFFICIENT, VOLTAGE-CONTROLLED LIGHT VALVES, E.G., WATCHES AND COMPUTERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0863895-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1998-09-16 | — | — | EP | disclosed |
| EP-0821719-A1 | LIQUID CRYSTAL COMPOUNDS HAVING A CHIRAL FLUORINATED TERMINAL PORTION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-02-04 | — | — | EP | disclosed |
| US-5702637-A | DISPLAY DEVICES WITH FAST RESPONSE TIMES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| WO-1997018203-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-22 | — | — | WO | disclosed |
| WO-1996033251-A1 | LIQUID CRYSTAL COMPOUNDS HAVING A CHIRAL FLUORINATED TERMINAL PORTION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-10-24 | — | — | WO | disclosed |
| JP-S5976039-A | (S)-2,3-DIACETYL-1-BENZYL GLYCEROL | TOA EIYOU KAGAKU KOGYO KK | 1984-04-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094984-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | EPHX1 1106/4885MEN1 2727/4885KMT2A 1384/4885 |
| US-20150352132-A1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | PMP22, MAG, SGMS1 | EPHX1 1090/4885MEN1 2496/4885KMT2A 2803/4885 |
| US-10413559-B2 | Method for treating demyelinating disease | PMP22, MAG, SGMS1 | EPHX1 797/4885MEN1 2540/4885KMT2A 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.